The BTD is for the treatment of paediatric patients aged three years and older with neurofibromatosis type 1 (NF1).
News
Circassia’s COPD drug gets FDA approval
The approval is based on data from three Phase III studies, ACLIFORM, AUGMENT and AMPLIFY.
NHS prescribed nearly 70M antidepressants last year as rates double in a decade
The number dispensed last year was almost double the 36 million recorded a decade ago in 2008.
FDA green light for Merck’s Mavenclad
The drug is the first oral MS treatment to provide two years of proven efficacy with a maximum of 20 days of treatment.
Novartis strengthens anti-inflammatory drugs portfolio with IFM Tre buy
The Swiss company will pay $310 million in upfront payments.
FDA label expansion for UCB’s Cimzia
The FDA has approved the drug for a certain type of inflammatory arthritis called non-radiographic axial spondyloarthritis.
No-deal Brexit could mean temporary medicines export ban
The ABPI has warned that “there a range of things outside of our control”.
Bluebird’s Zynteglo kicks off first Amsterdam CHMP recommendations
The European Medicines Agency’s CHMP positive opinions are sparse this time around.
J&J submits sNDA for Invokana after premature end to clinical trial
If approved, the drug will be the only therapy in nearly 20 years to reduce the risk of end-stage kidney disease.
Boots tests ‘behavioural nudge theory’ for medication adherence
The study found that patients warned of adverse consequences to their own health of skipping doses were more likely to adhere.
NICE backs PredictImmune’s IBD prognosis test
The CE-marked prognostic test for guiding treatment options uses a gene expression “signature”.
BMS signs deal with Concerto HealthAI
The partnership will give the American pharma giant access to Concerto’s eurekaHealth AI insights platform.
AstraZeneca and Daiichi sign $6.9bn cancer drug deal
The collaboration is aligned with AstraZeneca’s science-led strategy in oncology.
New pharma Azadyne raises £1.5m for autoimmune disease treatment
The Trinity College spin-off has completed a £1.5-million funding round for its autoimmune treatments.
NHS aims for one link worker per primary care network from July
The social prescription plan aims to bring about the major shift in perspective needed.
